FDA — authorised 12 December 2016
- Application: ANDA207456
- Marketing authorisation holder: SHILPA
- Status: supplemented
FDA authorised 150mg on 12 December 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 12 December 2016; FDA has authorised it.
SHILPA holds the US marketing authorisation.